BluePrint analyzes 80 different genes to classify your tumor into its own unique molecular subtype. Different molecular subtypes respond differently to different categories of drugs. High Risk patients can benefit by being further divided into subtypes that will help fine tune their treatment plans. BluePrint also identifies a specific subtype of patient who will not benefit from chemotherapy.
Molecular Subtyping for Breast Cancer
Recent clinical studies have found that a more personalized treatment plan can be developed when the physician understands the molecular subtype for breast cancer for that patient. Knowing the molecular subtype is especially important for those patients who are at a higher risk for breast cancer recurrence.